ArticleOrphanet journal of rare diseases2025
Left ventricular hypertrabeculation is a novel predictor of life-threatening arrhythmic events in long QT syndrome patients.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLong QT syndrome (LQTS) is a malignant cardiac channelopathy for patients with traditionally normal heart structures. Sporadic cases reported left ventricular hypertrabeculation (LVHT) was a deadly double hit in LQTS patients. Here we summarize the prevalence of LVHT within LQTS subjects and analyse the correlation of LVHT with life-threatening arrhythmic events (LAEs).
methodsThe study cohort consisted of 170 genotype-confirmed LQTS patients, which were classified to two groups, including non-left ventricular hypertrabeculation LQTS patients(LQTS-N-LVHT group) and LQTS-LVHT co-phenotype individuals (LQTS-LVHT group) according to the diagnosis criteria of LVHT. The primary endpoint was LAEs, defined as arrhythmogenic syncope, sustained ventricular tachycardia (VT), appropriate ICD shocks, sudden cardiac death.
resultsEight LQTS patients (8/170, 4.7%) in the cohort met diagnostic criteria of LVHT. No statistical difference in symptomatology, Schwartz score, QTc interval in electrocardiograms, and proportion of PVCs or torsade de points (Tdp) in ambulatory Holter monitoring was revealed between two groups. By contrast, LQTS-LVHT subjects had a higher ratio of documented VF in ambulatory Holter monitoring compared with LQTS-N-LVHT patients (LQTS-LVHT 2/8, 25.0% vs. LQTS-N-LVHT 3/111, 2.7%, p = 0.036). In total, 59 patients (59/170, 34.7%) developed LAEs during follow-up duration of 52.8 ± 32.3 months. Significant difference was found between two groups by the log-rank test (p < 0.001).A univariate Cox regression analysis was performed demonstrating that LVHT was a significant predictor of LAEs[HR: 4.02 (1.71-9.45), P = 0.001].A multivariate Cox regression analysis indicated that LVHT remained a predictor of LAEs [hazard ratio: 3.02 (1.24-7.36), p = 0.015].
conclusionLVHT is a novel predictor of life-threatening arrhythmic events in LQTS patients. Effective prevention treatment should be emphasized to prevent life-threatening cardiac events in LQTS-LVHT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.